| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase (NCT05007873) | M.D. Anderson Cancer Center | 2021-10-21 |
| Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT04329325) | Memorial Sloan Kettering Cancer Center | 2020-03-30 |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (NCT03512405) | City of Hope Medical Center | 2019-08-02 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers (NCT03589729) | M.D. Anderson Cancer Center | 2018-09-19 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03698552) | M.D. Anderson Cancer Center | 2018-08-24 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia (NCT03576547) | M.D. Anderson Cancer Center | 2018-06-26 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984) | University of Southern California | 2018-05-09 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (NCT03263572) | M.D. Anderson Cancer Center | 2017-11-29 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies (NCT03241940) | Stanford University | 2017-10-20 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (NCT03233854) | Stanford University | 2017-09-01 |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia (NCT02997761) | University of California, Davis | 2017-06-27 |
| Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease (NCT02458014) | M.D. Anderson Cancer Center | 2015-09-14 |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (NCT01424982) | M.D. Anderson Cancer Center | 2011-10-05 |
| Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (NCT01190930) | Children's Oncology Group | 2010-08-11 |
| Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (NCT01043874) | Novartis Pharmaceuticals | 2009-12-01 |
| Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (NCT00390793) | M.D. Anderson Cancer Center | 2006-09-28 |